FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

IPF is a progressive and fatal lung disease for which there are no FDA-approved therapies. FG-3019 was developed to inhibit the activity of CTGF, a matricellular protein that plays a key role in fibrosis. More than a decade of research conducted by FibroGen and others has established the critical role of CTGF as a final common pathway in chronic fibrotic diseases, in which persistent and excessive scarring leads to organ dysfunction and failure.

Orphan Drug Designation is generally granted to drugs or biologics intended for treatment of rare diseases and disorders, i.e., those affecting fewer than 200,000 people in the U.S. This designation conveys special incentives to the sponsor, including tax credit for fifty percent of the cost of clinical trials, prescription drug user fee waiver, and seven years of U.S. market exclusivity for the drug or biologic upon FDA approval.

"The granting of FibroGen's request for Orphan Drug Designation constitutes a major milestone in the development of FG-3019 for pulmonary fibrosis," said Thomas B. Neff, Chief Executive Officer of FibroGen. "We have been encouraged by early results from our ongoing phase 2 studies suggesting that sufficiently high bloodstream levels of FibroGen's FG-3019 antibody may prevent predicted decline in lung function and even increase lung capacity in some cases. We are committed to further clinical evaluation of FG-3019 in hopes of developing a safe and effective therapy that will provide IPF patients with a superior treatment outcome."

Source: FibroGen, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Kyushu University team develops antibody to fight age-related muscle atrophy